Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein
Key facts
| Invented name |
Cervarix
|
| Active substance |
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/11/2009
|
| PIP number |
Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Infection by Human Papillomavirus in females
|
| Route(s) of administration |
Intramuscular injection
|
| Contact for public enquiries |
GlaxoSmithKline Biologicals S.A.
E-mail: eu.paediatric-plans@gsk.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|